LOGIN  |  REGISTER

List of Medical Device Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 125.57
1.13 0.91
6.05M
1.73B
US$ 217.240B
US$ 467.53
15.94 3.53
2.65M
356.18M
US$ 166.520B
US$ 91.86
2.16 2.41
9.60M
1.47B
US$ 135.030B
US$ 347.82
2.02 0.58
2.85M
381.22M
US$ 132.600B
US$ 83.78
0.90 1.09
6.82M
1.28B
US$ 107.240B
US$ 206.92
-0.42 -0.20
2.56M
290.01M
US$ 60.010B
US$ 83.30
-0.52 -0.62
1.56M
494.60M
US$ 41.200B
US$ 69.30
-0.06 -0.09
3.20M
589.80M
US$ 40.870B
US$ 215.16
9.99 4.87
1.32M
146.80M
US$ 31.590B
US$ 106.89
-0.45 -0.42
983,169
199.07M
US$ 21.280B
US$ 215.00
2.38 1.12
456,092
98.71M
US$ 21.220B
US$ 257.95
12.69 5.17
725,080
70.14M
US$ 18.090B
US$ 73.80
0.03 0.04
1.29M
199.58M
US$ 14.730B
US$ 28.79
0.00 0.00
4.59M
510.59M
US$ 14.700B
US$ 201.43
-1.78 -0.88
809,713
72.42M
US$ 14.590B
US$ 61.97
1.11 1.82
2.51M
225.72M
US$ 13.990B
US$ 25.81
-0.50 -1.90
1.26M
435.99M
US$ 11.250B
US$ 265.55
3.27 1.25
282,411
38.38M
US$ 10.190B
US$ 151.62
7.22 5.00
673,735
53.54M
US$ 8.120B
US$ 70.42
1.59 2.31
1.09M
113.74M
US$ 8.010B
US$ 116.97
5.03 4.49
1.22M
56.03M
US$ 6.550B
US$ 131.21
-0.72 -0.55
566,080
46.44M
US$ 6.090B
US$ 38.81
2.35 6.45
2.94M
151.60M
US$ 5.880B
US$ 92.40
-0.10 -0.11
817,647
58.28M
US$ 5.390B
US$ 227.79
2.19 0.97
395,491
22.92M
US$ 5.220B
US$ 86.41
2.75 3.29
1.16M
55.14M
US$ 4.760B
US$ 79.97
0.00 0.00
0
58.56M
US$ 4.680B
US$ 151.77
9.83 6.93
657,330
29.97M
US$ 4.550B
US$ 11.70
-0.41 -3.39
419,097
352.16M
US$ 4.120B
US$ 113.24
-0.46 -0.40
389,067
33.54M
US$ 3.800B
US$ 70.98
0.00 0.00
0
51.11M
US$ 3.630B
US$ 143.22
3.90 2.80
261,690
24.48M
US$ 3.510B
US$ 98.98
-1.36 -1.36
272,102
31.30M
US$ 3.100B
US$ 59.72
-1.16 -1.91
551,832
50.22M
US$ 3.000B
US$ 50.54
-0.69 -1.35
871,352
54.11M
US$ 2.730B
US$ 69.30
1.63 2.41
1.21M
33.56M
US$ 2.330B
US$ 35.88
-0.07 -0.19
695,833
54.30M
US$ 1.950B
US$ 79.93
0.15 0.19
205,721
22.48M
US$ 1.800B
US$ 16.38
-0.11 -0.67
575,512
108.20M
US$ 1.770B
US$ 56.42
0.17 0.30
420,768
30.89M
US$ 1.740B
US$ 15.24
-0.54 -3.42
1.65M
101.66M
US$ 1.550B
US$ 31.58
0.27 0.86
280,025
48.75M
US$ 1.540B
US$ 19.73
0.16 0.82
401,201
77.16M
US$ 1.520B
US$ 10.08
-0.15 -1.47
2.63M
141.77M
US$ 1.430B
US$ 29.14
0.02 0.07
628,250
45.69M
US$ 1.330B
US$ 9.68
-0.42 -4.16
739,182
134.56M
US$ 1.300B
US$ 15.56
-0.16 -1.02
1.01M
76.25M
US$ 1.190B
US$ 16.68
-0.20 -1.18
1.54M
65.68M
US$ 1.100B
US$ 13.01
-0.04 -0.31
3.15M
83.72M
US$ 1.090B
US$ 7.08
0.02 0.28
453,050
146.95M
US$ 1.040B
US$ 21.24
0.36 1.72
620,514
46.39M
US$ 985.140M
US$ 23.14
-0.08 -0.34
255,001
41.92M
US$ 970.030M
US$ 15.21
0.13 0.86
73,153
61.52M
US$ 935.720M
US$ 18.73
-0.29 -1.52
240,465
49.60M
US$ 929.010M
US$ 31.40
-0.90 -2.79
675,452
28.76M
US$ 903.060M
US$ 16.04
0.12 0.75
935,437
49.28M
US$ 790.450M
US$ 22.69
0.44 1.98
961,357
33.60M
US$ 762.380M
US$ 16.74
0.52 3.21
305,963
44.01M
US$ 736.730M
US$ 16.27
0.01 0.06
800,307
40.30M
US$ 655.680M
US$ 18.20
-0.25 -1.36
52,784
35.82M
US$ 651.740M
US$ 50.91
0.99 1.98
19,969
12.67M
US$ 645.060M
US$ 12.92
-0.50 -3.73
279,635
45.96M
US$ 593.800M
US$ 13.48
0.01 0.07
279,812
41.94M
US$ 565.350M
US$ 14.37
-0.21 -1.44
197,788
38.21M
US$ 549.080M
US$ 22.12
-0.59 -2.60
294,996
24.22M
US$ 535.630M
US$ 8.15
-0.18 -2.16
307,911
65.37M
US$ 532.900M
US$ 9.86
-1.04 -9.50
114,126
52.94M
US$ 521.720M
US$ 3.68
-0.03 -0.81
763,847
128.81M
US$ 474.020M
US$ 7.50
-0.25 -3.23
235,112
62.30M
US$ 467.250M
US$ 10.83
-0.18 -1.63
412,388
36.20M
US$ 392.050M
US$ 2.08
0.04 2.01
2.63M
186.64M
US$ 388.400M
US$ 9.16
0.04 0.44
380,178
40.47M
US$ 370.500M
US$ 12.40
0.17 1.39
117,099
29.85M
US$ 370.140M
C$ 2.24
0.00 0.00
0
154.17M
C$ 345.340M
US$ 0.56
-0.0096 -1.68
7.96M
595.33M
US$ 335.170M
US$ 35.30
1.45 4.28
202,247
9.27M
US$ 327.230M
US$ 13.30
0.11 0.83
195,811
24.00M
US$ 319.200M
US$ 7.57
-0.71 -8.57
498,211
41.23M
US$ 312.110M
US$ 11.54
-0.18 -1.54
200,793
24.26M
US$ 279.960M
US$ 6.74
-0.14 -2.03
124,887
38.94M
US$ 262.460M
US$ 6.59
-0.17 -2.51
276,502
39.49M
US$ 260.240M
US$ 2.45
0.00 0.00
454,968
105.48M
US$ 258.430M
US$ 9.33
-0.14 -1.48
106,539
27.60M
US$ 257.510M
US$ 5.04
-0.91 -15.32
1.07M
49.57M
US$ 249.580M
US$ 4.22
-0.18 -4.09
1.87M
58.52M
US$ 246.950M
US$ 27.67
-0.12 -0.43
43,334
8.74M
US$ 241.790M
US$ 28.00
0.00 0.00
0
8.53M
US$ 238.840M
US$ 3.03
-0.09 -2.73
691,961
74.59M
US$ 225.630M
US$ 5.84
0.00 0.00
0
37.47M
US$ 218.820M
US$ 5.83
-0.25 -4.11
75,432
37.43M
US$ 218.030M
US$ 7.67
0.17 2.27
166,665
26.22M
US$ 201.110M
US$ 22.49
0.09 0.40
73,498
8.46M
US$ 190.220M
US$ 55.64
0.80 1.46
21,205
3.39M
US$ 188.600M
US$ 55.51
4.61 9.06
66,330
3.26M
US$ 180.960M
US$ 7.22
0.18 2.56
395,549
23.82M
US$ 171.980M
US$ 8.83
-0.02 -0.23
67,067
18.82M
US$ 166.180M
US$ 13.79
-0.06 -0.43
148,837
11.61M
US$ 160.100M
US$ 5.23
0.01 0.19
10,431
30.49M
US$ 159.460M
US$ 1.56
-0.01 -0.64
787,552
100.56M
US$ 156.870M
US$ 4.39
0.04 0.92
400,578
33.70M
US$ 147.940M
US$ 1.65
-0.02 -0.90
429,017
84.73M
US$ 139.380M
US$ 4.59
-0.42 -8.40
138,292
30.03M
US$ 137.690M
US$ 3.75
-0.06 -1.57
398,477
34.82M
US$ 130.570M
US$ 1.71
-0.10 -5.28
840,639
67.59M
US$ 115.240M
US$ 2.16
-0.14 -6.04
177,176
50.40M
US$ 108.910M
US$ 2.94
-0.28 -8.70
204,767
35.94M
US$ 105.660M
US$ 4.88
-0.03 -0.61
142,984
21.26M
US$ 103.750M
US$ 2.17
-0.11 -4.82
178,269
45.84M
US$ 99.470M
US$ 0.62
0.0034 0.55
45,732
156.55M
US$ 97.060M
US$ 1.55
0.11 7.64
1.44M
59.34M
US$ 91.980M
US$ 2.09
0.05 2.45
156,222
43.09M
US$ 90.060M
US$ 2.55
0.05 1.80
92,841
34.31M
US$ 87.320M
US$ 13.39
0.00 0.00
13,330
6.27M
US$ 83.920M
US$ 2.60
-0.11 -4.06
55,919
30.25M
US$ 78.650M
US$ 2.04
-0.15 -6.85
229,607
37.72M
US$ 76.950M
US$ 4.40
-0.06 -1.35
115,139
16.39M
US$ 72.120M
US$ 0.87
0.0001 0.01
44,720
77.89M
US$ 67.760M
US$ 2.12
-0.04 -1.85
254,789
31.85M
US$ 67.520M
US$ 2.51
-0.13 -4.92
29,332
26.08M
US$ 65.460M
US$ 0.47
0.00 0.00
5,819
139.01M
US$ 65.330M
US$ 1.15
0.01 0.88
255,475
56.57M
US$ 65.060M
US$ 3.50
0.00 0.00
0
17.86M
US$ 62.510M
US$ 0.98
0.005 0.52
28,279
60.93M
US$ 59.410M
US$ 0.97
0.01 1.35
69,119
59.23M
US$ 57.630M
US$ 1.51
-0.10 -6.21
132,597
37.10M
US$ 56.020M
US$ 1.10
-0.07 -5.64
186,675
49.57M
US$ 54.730M
US$ 3.21
0.41 14.64
47,060
16.04M
US$ 51.490M
US$ 20.01
0.00 0.00
0
2.54M
US$ 50.830M
US$ 0.11
-0.0008 -0.70
175,724
417.59M
US$ 47.610M
US$ 5.20
0.73 16.33
461,708
8.27M
US$ 43.000M
US$ 1.52
0.03 2.08
771,229
28.03M
US$ 42.630M
C$ 0.17
-0.01 -5.56
417,270
247.78M
C$ 42.120M
C$ 0.44
-0.02 -3.33
10,250
93.38M
C$ 40.620M
US$ 0.70
0.04 5.59
278,383
57.89M
US$ 40.350M
US$ 1.00
-0.08 -7.41
147,578
39.39M
US$ 39.390M
US$ 2.23
-0.06 -2.62
109,674
17.54M
US$ 39.110M
US$ 1.00
0.01 1.01
48,427
37.64M
US$ 37.640M
US$ 5.61
-0.05 -0.88
105,371
6.55M
US$ 36.750M
C$ 0.30
0.005 1.72
4,000
119.77M
C$ 35.330M
US$ 0.83
-0.05 -5.57
238,899
40.14M
US$ 33.360M
C$ 0.27
-0.02 -7.02
126,150
113.10M
C$ 29.970M
US$ 5.56
-0.01 -0.18
24,596
5.25M
US$ 29.170M
US$ 1.18
-0.02 -1.26
208,790
22.90M
US$ 26.910M
US$ 1.27
-0.16 -10.92
11,585
20.24M
US$ 25.600M
US$ 1.18
-0.03 -2.48
183,427
20.75M
US$ 24.480M
C$ 0.32
0.00 0.00
0
77.42M
C$ 24.390M
US$ 1.69
-0.004 -0.24
86,136
13.30M
US$ 22.420M
C$ 0.14
-0.01 -6.67
83,500
159.67M
C$ 22.350M
US$ 0.69
0.01 1.47
16,001
29.94M
US$ 20.660M
US$ 1.80
-0.24 -11.76
18,093
10.54M
US$ 18.970M
US$ 2.42
0.06 2.54
20,358
7.26M
US$ 17.570M
US$ 2.57
0.002 0.08
31,093
6.79M
US$ 17.460M
US$ 0.24
-0.0066 -2.73
1.16M
72.19M
US$ 16.960M
US$ 2.36
0.52 28.42
125,591
7.09M
US$ 16.700M
C$ 0.06
0.00 0.00
0
270.17M
C$ 16.210M
US$ 0.37
-0.03 -7.32
170,605
43.62M
US$ 16.180M
US$ 2.55
0.00 0.00
48,595
5.89M
US$ 14.990M
US$ 1.40
-0.07 -4.76
293,196
10.63M
US$ 14.880M
US$ 0.47
-0.01 -2.11
772,147
30.84M
US$ 14.340M
US$ 0.84
-0.02 -2.54
113,290
16.64M
US$ 13.980M
US$ 0.58
-0.01 -1.69
401,439
22.45M
US$ 13.020M
US$ 0.55
-0.06 -9.67
600
20.63M
US$ 11.370M
US$ 2.51
-0.08 -2.97
636
4.17M
US$ 10.480M
US$ 2.74
0.38 16.10
37,764
3.75M
US$ 10.280M
C$ 0.05
0.00 0.00
20,555
217.73M
C$ 9.800M
US$ 0.29
-0.02 -5.97
138,229
31.90M
US$ 9.350M
US$ 0.51
0.0058 1.16
113,658
18.34M
US$ 9.280M
C$ 0.02
0.00 0.00
1.22M
451.63M
C$ 9.030M
US$ 4.37
-0.04 -0.91
3,096
2.04M
US$ 8.910M
US$ 0.50
-0.01 -2.33
52,071
17.23M
US$ 8.670M
US$ 0.34
-0.08 -18.19
5,341
24.39M
US$ 8.270M
US$ 1.35
-0.04 -2.88
119,500
6.00M
US$ 8.100M
US$ 1.21
-1.90 -61.09
9,039
6.63M
US$ 8.020M
US$ 1.27
0.00 0.00
0
6.24M
US$ 7.920M
US$ 0.36
-0.02 -4.76
198,548
22.00M
US$ 7.920M
US$ 1.17
-0.17 -12.69
390,758
6.67M
US$ 7.800M
US$ 0.10
0.00 0.00
0
73.90M
US$ 7.390M
US$ 2.70
-0.20 -6.90
95,301
2.71M
US$ 7.320M
US$ 0.58
-0.02 -2.86
128,686
11.07M
US$ 6.400M
US$ 0.43
-0.06 -12.24
191,555
14.59M
US$ 6.270M
US$ 1.29
-0.06 -4.44
87,517
4.81M
US$ 6.200M
US$ 0.36
-0.0069 -1.89
102,420
13.96M
US$ 5.010M
US$ 0.31
0.00 0.00
0
15.85M
US$ 4.920M
US$ 8.21
4.68 132.58
55.32M
552,854
US$ 4.540M
US$ 0.35
0.00 0.00
0
11.88M
US$ 4.170M
US$ 1.13
-0.07 -5.83
663,424
3.14M
US$ 3.550M
US$ 0.77
-0.06 -7.23
76,337
4.37M
US$ 3.360M
US$ 1.57
-0.07 -4.27
14,142
1.77M
US$ 2.780M
US$ 2.69
-0.02 -0.68
14,457
980,321
US$ 2.640M
US$ 0.30
-0.02 -7.34
259,545
8.00M
US$ 2.380M
US$ 1.07
0.00 0.00
0
1.82M
US$ 1.940M
US$ 0.17
-0.0001 -0.06
8,000
10.59M
US$ 1.800M
US$ 0.73
0.005 0.69
46,550
2.46M
US$ 1.780M
US$ 0.47
0.00 0.00
0
3.20M
US$ 1.520M
US$ 0.04
-0.05 -53.33
19,666
29.91M
US$ 1.260M
US$ 0.32
-0.07 -17.95
131,403
3.73M
US$ 1.190M
US$ 0.20
0.00 0.00
0
5.24M
US$ 1.050M
US$ 0.009
-0.0005 -5.26
18,000
96.71M
US$ 870K
US$ 0.10
-0.006 -5.66
9,496
7.26M
US$ 726K
US$ 0.35
-0.25 -41.67
5,150
1.78M
US$ 623K
US$ 1.20
0.00 0.00
0
418,049
US$ 502K
US$ 0.46
0.001 0.22
19.25M
729,980
US$ 337K
C$ 0.005
0.00 0.00
229,000
59.81M
C$ 299K
US$ 0.02
-0.0058 -22.48
58.26M
2.05M
US$ 41K
US$ 0.00
0.00 0.00
0
40.35M
US$ -
US$ 0.00
0.00 0.00
0
855.04M
US$ -
C$ 0.60
0.00 0.00
29
-
C$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -

Latest News From Medical Device Stocks


NEXGEL to Present at the Planet MicroCap Showcase in Las Vegas, NV April 22nd-24th 

LANGHORNE, Pa., April 07, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will be presenting at the Planet MicroCap Showcase: Vegas 2025, taking place at the Paris Hotel & Casino, Las Vegas, NV on April 22-24,... Read more


Inspira Technologies Announces Successful Treatment of First Patient with INSPIRA ART100 at Westchester Medical Center

RA'ANANA, Israel, April 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced the successful completion of the first human treatment using its U.S. Food and Drug Administration-cleared INSPIRA™ ART100 system in a critical life-support procedure. The procedure was successfully performed by expert physicians at Westchester... Read more


BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company

Strategic acquisition enhances biopreservation media portfolio with novel Ice Recrystallization Inhibitor technology Marks the second acquisition from Bioproduction Innovation Accelerator program BOTHELL, Wash., April 7, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the... Read more


ICU Medical Introduces Its New Category of Infusion Devices With FDA Clearances of Plum Solo™ and Plum Duo™ Precision IV Pumps

New devices address infusion delivery variability and expand the ICU Medical IV Performance Platform. SAN CLEMENTE, Calif., April 7, 2025 /PRNewswire/ -- ICU Medical Inc. (NASDAQ:ICUI), a worldwide leader in the development, manufacture and sale of innovative medical devices, has announced 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Plum Solo™ precision IV pump, a single-channel complement to the dual-channel Plum Duo™.... Read more


Insulet Launches Omnipod® 5 Automated Insulin Delivery System in Canada, a Revolutionary New Technology for People Living with Type 1 Diabetes Ages Two Years and Above

New Diabetes Canada Guidelines1 recommend people with type 1 diabetes use an Automated Insulin Delivery System (AID) System for diabetes management Approximately 300,000 Canadians have type 1 diabetes, with the number of cases growing at an estimated 4.4% per year2 The Omnipod 5 System is designed to be customer-centric and aims to deliver exceptional ease of use. It has demonstrated strong clinical results including lower A1c and improved time in range, while... Read more


Theralase Technologies: Ruvidar Demonstrates 7 Year Complete Response

Patient Diagnosed with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ Treated Once with Light-Activated Ruvidar(TM) Demonstrates 7 Year Complete Response Toronto, Ontario--(Newsfile Corp. - April 7, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small... Read more


Bruker Announces First-of-a-kind 1.3 GHz High-Resolution NMR System

Novel hybrid LTS-HTS superconducting magnet enables high-resolution for liquids and solids ultra-high field NMR research in biomolecular and advanced materials sciences ASILOMAR, Calif. / Apr 07, 2025 / Business Wire / At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the successful development and testing of the world’s first high-resolution 1.3 GHz NMR spectrometer... Read more


Bruker Introduces Innovative Fourier 80 Multinuclear Benchtop FT-NMR

Unique Fourier 80 ‘Multi-Talent’ offers 1H NMR and choice of 15 X-nuclei with just one click ASILOMAR, Calif. / Apr 07, 2025 / Business Wire / At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the launch of an innovative Fourier 80 multinuclear benchtop FT-NMR spectrometer, known as the ‘Multi-Talent’ configuration. This novel Fourier 80 ‘Multi-Talent’ system... Read more


Treace Medical Concepts Announces Upcoming Board Chair Transition

PONTE VEDRA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that its Board of Directors has appointed John. T. Treace, Chief Executive Officer and Founder of Treace, as the Chairman of the Board to... Read more


AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity

VALENCIA, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the U.S. commercial launch of Cohealyx™, a collagen-based dermal matrix branded by AVITA Medical and co-developed with Regenity Biosciences. Cohealyx is designed to facilitate cellular migration and revascularization, thereby providing an ideal wound bed for definitive closure.... Read more


Electromed to Present at the LD Micro Invitational XV

New Prague, Minnesota--(Newsfile Corp. - April 3, 2025) - Electromed, Inc. (NYSE American: ELMD) announced today that it will be participating in the 15th Annual LD Micro Invitational at the Westin Grand Central in New York on April 9th and 10th, 2025. Electromed, Inc. is scheduled to present on April 10, 2025 at 02:30 PM. Jim Cunniff, President and Chief Executive Officer, will be representing the company. Interested parties may register to access the live webcast of... Read more


Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US

SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test, NightOwl™, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT) designed to offer healthcare providers a simplified, accurate, and efficient way to diagnose obstructive sleep apnea (OSA) from the comfort of an... Read more


Autonomix Medical to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO)

THE WOODLANDS, TX, April 03, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced an abstract detailing its technology and early proof-of-concept study results has been accepted for poster presentation at the 2025 European Conference on Interventional Oncology (ECIO), being held April 13-16, 2025 in Rotterdam, Nether... Read more


NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting

MOUNTAIN VIEW, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, will be attending and presenting at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, which is being held in San Diego from April 5 – 9. This includes an oral presentation on data from the Post-Approval Study (PAS) of the RNS® System in adults treated with brain-responsive... Read more


Accuray CyberKnife® Platform Featured in New Studies Showcasing its Benefits in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting

Data Also Highlights Continued Clinical Advances Using the CyberKnife System That are Making High Quality Care an Option for People Who Previously Had Limited Choices MADISON, Wis., April 3, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data on the clinical use of the CyberKnife® System reinforce the device's broad-based radiation treatment capabilities for central nervous system (CNS) tumors. Malignant brain and other CNS tumors... Read more


NeuroOne Medical Technologies Announces Proposed Public Offering of Common Stock

EDEN PRAIRIE, Minn., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has commenced a proposed underwritten registered public offering of shares of its common stock. All of the shares of common stock to be sold in the proposed offering will be sold... Read more


RxSight Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance

ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary revenue results for the first quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Thursday, April 3, 2025, at 8:00 a.m. Eastern Time. Preliminary First Quarter 2025 Resul... Read more


Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes

Introduction of EluPro at Heart Rhythm 2025 in San Diego, April 25-27, 2025 SILVER SPRING, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, is proud to announce the debut of its EluPro™ Antibiotic-Eluting BioEnvelope designed for cardiac implantable electronic devices (CIEDs) and neurostimulators at the Heart Rhythm Society’s annual meeting (HRS 2025).... Read more


Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits

ALAMEDA, Calif., April 2, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced seven significant computer assisted vacuum thrombectomy (CAVT™) data presentations during the 2025 Society of Interventional Radiology (SIR) Annual Scientific Meeting. The data showed that CAVT as a frontline therapy for blood clots not only improved clinical and functional outcomes but can also help reduce overall healthcare costs.  "With... Read more


Masimo to Present in the 24th Annual Needham Virtual Healthcare Conference

IRVINE, Calif. / Apr 02, 2025 / Business Wire / Masimo (NASDAQ: MASI) today announced that its management will participate in the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 2:15 p.m. Eastern time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ: MASI) is a global medical technology company... Read more


Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has successfully enrolled the first patients in its clinical trial at the University of California, San Diego (UCSD), in collaboration with the VA San Diego Healthcare System (San Diego VA). The company began treatment of the first patients... Read more


Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter

Clareon PanOptix Pro provides unprecedented 94% light utilization, resulting in half the light scatter of Clareon PanOptix1,2,§,* Clareon PanOptix Pro provides more uninterrupted light distribution across the full visual range, and is designed for better image contrast1,† Commercially available in the U.S. in May, Clareon PanOptix Pro is the next generation of the world’s leading trifocal IOL3-5,‡ GENEVA / Apr 02, 2025 / Business Wire / Alcon (SIX/NYSE: ALC),... Read more


Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities

Akoya’s technology to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research, funded through the Cancer Grand Challenges initiative The unprecedented scale of the initiative requires the high plex and high throughput of Akoya’s PhenoCycler-Fusion platform to process thousands of patients' samples MARLBOROUGH, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, and... Read more


Aurora Spine Announces Publication of Biomechanical Study Demonstrating Superiority of SiLO TFX™ Sacroiliac Fusion System

CARLSBAD, California, April 02, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the publication of a new clinical study titled "Fixation of the Sacroiliac Joint: A Cadaver-Based Concurrent-Controlled Biomechanical Comparison of Posterior Interposition and Posterolateral Transosseous Techniques" in... Read more


Bruker Announces Introduction of Revolutionary d-DNP Polarizer for MRI Research and for Dynamic Nuclear Polarization Liquids NMR

First successful customer installation of novel dissolution d-DNP Polarizer at UCSF SAN FRANCISCO / Apr 02, 2025 / Business Wire / Bruker Corporation today announced the introduction of its groundbreaking dissolution Dynamic Nuclear Polarization (d-DNP) Polarizer at the 2025 Hyperpolarized Carbon-13 MRI Technology Development Workshop at the University of California San Francisco (UCSF) Hyperpolarized MRI Technology Resource Center. The first customer installation of... Read more


AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

LATHAM, N.Y. / Apr 02, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2025, which ended February 28, 2025. Fiscal Year 2025 Third Quarter Highlights   Quarter Ended... Read more


LeMaitre Vascular to Present at the 24th Annual Needham Virtual Healthcare Conference

BURLINGTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will present at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 3:45 PM EDT. About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable... Read more


Milestone Scientific Expands CompuFlo® Epidural System Footprint with InfiniSurg in New Jersey

ROSELAND, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that InfiniSurg, LLC, a premier ambulatory surgery center based in New Jersey, has incorporated the CompuFlo® Epidural System into its clinical practice. The device will be utilized by Roman Kosiborod, DO, a highly experienced anesthesiologist and pain management... Read more


Beyond Air: NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer’s Disease and Reinforcing Platform’s Strength Across Neurological Disor

BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers, and Alzheimer’s disease, and a subsidiary of Beyond Air (NASDAQ: XAIR), proudly announces the publication of breakthrough research by its Chief Scientific Officer, Prof. Haitham Amal, in Translational Psychiatry, a peer-reviewed medical journal published... Read more


Zimmer Biomet Receives CE Mark Approval for RibFix Advantage® Fixation System

Expanding Thoracic Portfolio WARSAW, Ind., and ZUG, Switzerland, April 1, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today announced its RibFix Advantage® Fixation System has received CE Mark certification – the first CE Mark for an intrathoracic rib fixation system. The RibFix Advantage Fixation System is intended for the thoracoscopic fixation, stabilization and fusion of rib fractures1,... Read more


Teleflex Receives FDA 510(k) Clearance of the AC3 Range™ Intra-Aortic Balloon Pump (IABP)

WAYNE, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced FDA 510(k) clearance of the AC3 Range™ Intra-Aortic Balloon Pump (IABP). Leveraging the patented technology of the AC3 Optimus™ IABP, the AC3 Range™ IABP is designed to provide reliable, ongoing IABP support across various patient transport modes, including ambulances and both fixed- and rotary-wing aircrafts. The AC3... Read more


InfuSystem Announces CEO Transition; Carrie Lachance to Become Chief Executive Officer

The Company Reaffirms Full Year 2025 Guidance: Revenue Growth of 8-10% and Adjusted EBITDA (non-GAAP) margin greater than 18.8% ROCHESTER HILLS, Mich. / Apr 01, 2025 / Business Wire / InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that Richard DiIorio will be stepping... Read more


Quanterix Showcases Innovation Powered by Simoa® at AD/PD with Customer Research and New Dried Blood Spot Extraction Kit

Simoa® technology highlighted in more than 80 posters and oral presentations demonstrating its impact on neurodegenerative disease research BILLERICA, Mass. / Apr 01, 2025 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the inclusion of a new dried blood spot extraction (DBS) kit as part of their industry-leading Simoa® assay kits at the International Conference... Read more


Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update

PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended December 31, 2024, and provided a corporate update. The Company reported a... Read more


Myomo to Present at the 24th Annual Needham Virtual Healthcare Conference

BURLINGTON, Mass. / Mar 31, 2025 / Business Wire / Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, president and chief executive officer and David Henry, chief financial officer, will present at the 24th Annual Needham Virtual Healthcare Conference, being held from April 7th... Read more


Edwards Lifesciences: New Data Confirm Rapid, Unpredictable Progression of Severe Aortic Stenosis and Need for Urgent Referral and Evaluation of Patients

CHICAGO / Mar 31, 2025 / Business Wire / Edwards Lifesciences (NYSE: EW) today announced new scientific evidence presented and published during the American College of Cardiology’s (ACC) Annual Scientific Session & Expo, addressing the critical needs of patients with structural heart disease. Without treatment, 1 in 10 patients experiencing symptoms of severe aortic stenosis (AS) may die within five weeks. However, the symptoms of severe AS can be difficult to detect... Read more


enVVeno Medical: The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Sympo

IRVINE, CA / ACCESS Newswire / March 31, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced its abstract has been accepted for presentation at the Society for Clinical Vascular Surgery (SCVS) 52nd Annual Symposium being held March 29-April 2, 2025 in Austin, TX. As part of the SCVS Symposium, Dr. Cassius Iyad Ochoa Chaar, Associate Professor of Surgery,... Read more


New Late-Breaking Data Reinforce Benefits of Abbott's TriClip™ for People With Leaky Tricuspid Heart Valve

TRILUMINATE™ Pivotal data presented at the American College of Cardiology's Annual Scientific Session (ACC.25) and simultaneously published in Circulation show the Abbott TriClip system reduces heart failure hospitalizations The latest results highlight significant improvements in tricuspid regurgitation and quality of life through two years ABBOTT PARK, Ill., March 31, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from its TRILUMIN... Read more


Intelligent Bio Solutions Expands Middle East Market Reach with Arabic Integration in Drug Screening System

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has integrated Arabic as the second international language to its Intelligent Fingerprinting Drug Screening System as part of the Company’s multilingual upgrade. The addition of Arabic follows INBS’s previously announced expansion plans... Read more


iRhythm Technologies Unveils New Real-World Data at ACC.25 Demonstrating the Benefits of Zio® Long-Term Continuous Monitoring for Arrhythmia Detection

SAN FRANCISCO, March 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced results from two large real-world retrospective analyses presented at the American College of Cardiology (ACC) 2025 Scientific Sessions in Chicago, IL. Drawing on data from more than 1.1 million patients who used iRhythm’s Zio® long-term continuous monitoring (LTCM) ECG devices, these studies demonstrate that short-term (24–48-hour) monitoring, such as with Holter... Read more


Nano-X Imaging Announces Fourth Quarter of 2024 Financial Results and Provides Business Updates

Recorded noted regulatory successes with FDA general use clearance and granting of CE Mark in the EU Advanced commercialization globally, signing new customer and channel partner agreements for Nanox.ARC and Nanox AI Management to host conference call and webcast Monday, March 31, 2025 at 8:30 AM ET PETACH TIKVA, Israel, March 31, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology... Read more


TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery

MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on advancing soft-tissue reconstruction solutions, today announced the U.S. launch of larger sizes of OviTex PRS Reinforced Tissue Matrix, the only tissue-based device reinforced with polymer suture embroidery specifically engineered for plastic and reconstructive surgery. Designed for consistency in thickness, stretch, permeability, and... Read more


Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Successful initial administration and full enrollment in first-in-human LIBERATE-1™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025 Positive NPM-139 (semaglutide implant) preclinical weight loss data comparable to injections of semaglutide, active ingredient in Ozempic®/Wegovy®, with potential for once-yearly dosing Additional $8.25M equity financing which secures solid financial position into... Read more


CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

2024 marked by strong commercial execution and improved operating leverage Company continues to expect DrugSorb-ATR regulatory decisions from Health Canada and US FDA in 2025 Successful Rights Offering and exercise of Series A Right Warrants strengthens balance sheet Strengthening of clinical portfolio across cardiac surgery and critical care in 2025 with new presentations and publications The Company has now adopted the standard accounting convention of reporting... Read more


Envoy Medical Reports Fourth Quarter and Full Year 2024 Financial Results

Company Provides Corporate Update that Includes Information on its Progress Enrolling Subjects in its Pivotal Clinical Study for Breakthrough Device, the Fully Implanted Acclaim® Cochlear Implant White Bear Lake, Minnesota--(Newsfile Corp. - March 31, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter... Read more


Venus Concept Announces Fourth Quarter and Fiscal Year 2024 Financial Results

TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and twelve months ended December 31, 2024. Summary of Financial Results & Recent Progress: Company continues to execute against Transformation Plan Cash used in operations in 2024 of $11.1 million, down 14% year-over-year The Company achieved a substantial... Read more


Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

Year over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep... Read more


Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients

GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut™ transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes. The findings... Read more


Treace Medical Concepts Announces Clinical Study Data Demonstrating Positive Lapiplasty® and Adductoplasty® Outcomes at the 2025 ACFAS Annual Scientific Conference

PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the presentation of updated interim data for the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies, as... Read more


Retractable Technologies Reports Results for 2024

LITTLE ELM, Texas / Mar 28, 2025 / Business Wire / Retractable Technologies, Inc. (NYSE American: RVP) reports the following information relating to the year ended December 31, 2024. Further details concerning the results of operations as well as other matters are available in Retractable’s Form 10-K filed on March 28, 2025 with the U.S. Securities and Exchange Commission. The Company’s revenues for 2024 decreased 24.2%. The Company’s revenues were approximately $33.0... Read more